This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fernández-Santana, V.
Right arrow Articles by Verez-Bencomo, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fernández-Santana, V.
Right arrow Articles by Verez-Bencomo, V.

 Previous Article  |  Next Article 

Infection and Immunity, December 2004, p. 7115-7123, Vol. 72, No. 12
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.12.7115-7123.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Antigenicity and Immunogenicity of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b

V. Fernández-Santana,1* Félix Cardoso,1 Arlene Rodriguez,2 Tania Carmenate,1 Luis Peña,1 Yuri Valdés,1 Eugenio Hardy,2 Fatme Mawas,3 Lazaro Heynngnezz,2 Maria C. Rodríguez,1 Ignacio Figueroa,1 Janoi Chang,1 Maria E. Toledo,4 Alexis Musacchio,2 Ibis Hernández,4 Mabel Izquierdo,2 Karelia Cosme,2 Rene Roy,5 and V. Verez-Bencomo1

Center for the Study of Synthetic Antigens, Facultad de Química, Universidad de la Habana,1 Center for Genetic Engineering and Biotechnology, Cubanacan, Playa,2 Institute for Tropical Medicine "Pedro Kouri," Autopista Novia del Mediodía, La Lisa, Havana, Cuba,4 National Institute for Biological Standard and Control, Blanche Lane, South Mimms, United Kingdom,3 Department of Chemistry, Université du Québec à Montréal, Montreal, Québec, Canada5

Received 6 April 2004/ Returned for modification 1 June 2004/ Accepted 6 July 2004

Polysaccharide-protein conjugates as vaccines have proven to be very effective in preventing Haemophilus influenzae type b infections in industrialized countries. However, cost-effective technologies need to be developed for increasing the availability of anti-H. influenzae type b vaccines in countries from the developing world. Consequently, vaccine production with partially synthetic antigens is a desirable goal for many reasons. They may be rigidly controlled for purity and effectiveness while at the same time being cheap enough that they may be made universally available. We describe here the antigenicity and immunogenicity of several H. influenzae type b synthetic oligosaccharide-protein conjugates in laboratory animals. The serum of H. influenzae type b-immunized animals recognized our synthetic H. influenzae type b antigens to the same extent as the native bacterial capsular polysaccharide. Compared to the anti-H. influenzae type b vaccine employed, these synthetic versions induced similar antibody response patterns in terms of titer, specificity, and functional capacity. The further development of synthetic vaccines will meet urgent needs in the less prosperous parts of the world and remains our major goal.

* Corresponding author. Mailing address: Center for the Study of Synthetic Antigens, Facultad de Química, Universidad de La Habana, Havana, Cuba 10400. Phone: 5378702331. Fax: 5378792331. E-mail: violeta{at}fq.uh.cu.

Editor: D. L. Burns

Infection and Immunity, December 2004, p. 7115-7123, Vol. 72, No. 12
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.12.7115-7123.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Safari, D., Dekker, H. A. T., Joosten, J. A. F., Michalik, D., de Souza, A. C., Adamo, R., Lahmann, M., Sundgren, A., Oscarson, S., Kamerling, J. P., Snippe, H. (2008). Identification of the Smallest Structure Capable of Evoking Opsonophagocytic Antibodies against Streptococcus pneumoniae Type 14. Infect. Immun. 76: 4615-4623 [Abstract] [Full Text]  
  • Torano, G., Toledo, M. E., Baly, A., Fernandez-Santana, V., Rodriguez, F., Alvarez, Y., Serrano, T., Musachio, A., Hernandez, I., Hardy, E., Rodriguez, A., Hernandez, H., Aguilar, A., Sanchez, R., Diaz, M., Muzio, V., Dfana, J., Rodriguez, M. C., Heynngnezz, L., Verez-Bencomo, V. (2006). Phase I Clinical Evaluation of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b in Human Adult Volunteers.. CVI 13: 1052-1056 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»